Abstract
In the LATITUDE study, abiraterone acetate plus prednisone (AAP) added to androgen deprivation therapy demonstrated significant overall survival (OS) benefit in patients with high-risk metastatic castration-sensitive prostate cancer (mCSPC), compared with placebo (PBO). Around 60% of patients received life-extending subsequent therapies (LEST) after PBO discontinuation. To our knowledge, this is the first analysis to estimate the real treatment effect adjusting for patients without LEST.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
